SHANGHAI, June 28, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States, announced that it has been selected as one of the Top Ten Outsourcing Enterprise in China for 2012 by China's Ministry of Commerce (MOC). The list was announced at China's Fifth Annual International Service Outsourcing Cooperation Conference, held in Nanjing on June 20, 2012. WuXi PharmaTech is the only life science R&D service company among the top ten outsourcing enterprises.
Because of its creative business model of serving life science R&D industry and contribution to China's life science industry, WuXi PharmaTech has been selected into the Top 10 list for five consecutive years since the selection was initiated in 2008 by MOC. Earlier in 2011, Dr. Ge Li, Chairman and CEO, was named a Top Ten Contributor to China's Outsourcing Industry.
"We are honored to be consistently recognized as a top outsourcing company in China," Dr. Li said. "This speaks volume for WuXi's service business model. As a leading life science R&D service company, we will strive to improve our capabilities and capacities to better serve our pharmaceutical, biotechnology and medical device customers and partners, to help bring new products into market sooner and more cost effectively to benefit patients in needs."
Issued annually by Council for International Investment Promotion (CCIIP), a non-profit organization under Ministry of Commerce, the Top Ten Outsourcing Chinese Enterprise List recognizes the best outsourcing enterprises in China that have achieved great business growth on a yearly basis.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit http://www.wuxiapptec.com or contact:
Aaron Shi (for the media)
Ronald Aldridge (for investors)
SOURCE WuXi PharmaTech (Cayman) Inc.